Zentalis Pharma Q2 EPS $(1.24) Misses $(0.84) Estimate; $426.4M Cash, Cash Equivalents And Marketable Securities As Of June 30, 2024
Portfolio Pulse from Benzinga Newsdesk
Zentalis Pharma (NASDAQ:ZNTL) reported Q2 EPS of $(1.24), missing the analyst estimate of $(0.84) by 47.62%. The company has $426.4M in cash, cash equivalents, and marketable securities as of June 30, 2024. This represents a 32.97% improvement over the same period last year.
August 09, 2024 | 11:12 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Zentalis Pharma reported a Q2 EPS of $(1.24), missing the analyst estimate of $(0.84) by 47.62%. Despite the miss, the company has $426.4M in cash and equivalents, showing a 32.97% improvement YoY.
The significant EPS miss is likely to negatively impact the stock price in the short term. However, the substantial cash reserves and year-over-year improvement in losses may provide some support.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100